Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

suPAR ≥6 ng/mL for Predicting Severe Respiratory Failure in U.S. Adults Hospitalized With COVID 19 (suPAR US The Michigan Cohort Heterogeneity Study)

NCT07466524 is registered in ClinicalTrials.gov with ViroGates A/S as lead sponsor.

NCT NCT07466524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07466524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
suPAR ≥6 ng/mL for Predicting Severe Respiratory Failure in U.S. Adults Hospitalized With COVID 19 (suPAR US The Michigan Cohort Heterogeneity Study)
Lead sponsor
ViroGates A/S
Phase
Observational
Overall status
Completed
Start date
February 1, 2020
Completion date
October 19, 2022
Enrollment
367 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory distress syndrome, covid-19, severe respiratory distress syndrome